EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Adult Height Following Prepubertal Treatment With Antiandrogen, Aromatase Inhibitor, and Reduced Hydrocortisone in CAH

Deborah P Merke iD, Ashwini Mallappa iD, Megan Parker, Charles Sukin, Sarah E Kulkarni, Margaret F Keil iD, Carol Van Ryzin, Suvimol Chirathivat Hill, James C Reynolds, Gordon B Cutler iD, Ninet Sinaii iD

The Journal of Clinical Endocrinology & Metabolism · 2025

DOI: 10.1210/clinem/dgae824 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Deborah P Merke und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, National Institutes of Health Clinical Center, Bethesda, MD 20892, USA. Hauptthemen laut MEDLINE: Hydrocortisone, Aromatase Inhibitors, Body Height, Adrenal Hyperplasia, Congenital. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Institute of Child Health and Human Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Height outcome in patients with classic congenital adrenal hyperplasia (CAH) is suboptimal due to glucocorticoid and androgen excess.

Methods

In an open, randomized, controlled trial, children with classic CAH were randomized to receive a combination regimen of antiandrogen, aromatase inhibitor, reduced hydrocortisone, and fludrocortisone prior to puberty or standard therapy (hydrocortisone, fludrocortisone). Females continued on antiandrogen during puberty. The primary endpoint was adult height.

Results

Of 62 children randomized, 45 completed the study. Adult height SDS did not differ between the investigational and control groups (−0.34 [0.93] vs −0.60 [0.89], respectively), mean difference 0.26 [95% CI −0.29, 0.82], P = .35), irrespective of midparental height, but was greater than the predicted adult height pretreatment in both groups (P < .001). Growth rate and rate of bone maturation were reduced in the investigational group prior to puberty, despite lower hydrocortisone dose (7.6 [1.5] vs 15.0 [3.6] mg/m2/day, P < .001), and improvement in predicted adult height appeared greater at pubertal onset (P = .049) compared to standard therapy. Antiandrogen treatment during puberty in girls allowed for lower-dose glucocorticoid, and improved height outcome (adult minus midparental height: −0.7 [4.6] vs −5.6 [5.2] cm, mean difference 4.9 [95% CI 0.09, 9.7], P = .046). Those who received GnRHa had lower growth rate (P = .023) and longer years of unchanged bone age (P = .017), regardless of treatment.

Conclusion

Prepubertal antiandrogen, aromatase inhibitor combination with reduced hydrocortisone improves short-term predicted height for children with CAH but does not result in taller adult stature than those treated with standard therapy, and is not recommended. Females may benefit from antiandrogen treatment during puberty.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HydrocortisoneAromatase InhibitorsBody HeightAdrenal Hyperplasia, CongenitalAndrogen AntagonistsHumansFemaleChildPubertyDrug Therapy, CombinationAdolescentAdultChild, PreschoolMaleFludrocortisoneTreatment Outcome

Stichwörter der Autor:innen

CAHadult heightantiandrogenaromatase inhibitorcongenital adrenal hyperplasia

Substanzen

HydrocortisoneAromatase InhibitorsAndrogen AntagonistsFludrocortisone

Autor:innen und Institutionen

  • Department of Pediatrics, National Institutes of Health Clinical Center, Bethesda, MD 20892, USA.
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892, USA.

ORCID-Profile: Deborah P Merke, Ashwini Mallappa, Margaret F Keil, Gordon B Cutler, Ninet Sinaii

Förderung

  • National Institute of Child Health and Human Development

Zitieren

APA

Merke, D. P., Mallappa, A., Parker, M., Sukin, C., Kulkarni, S. E., Keil, M. F., Van Ryzin, C., Hill, S. C., Reynolds, J. C., Cutler, G. B., & Sinaii, N. (2025). Adult Height Following Prepubertal Treatment With Antiandrogen, Aromatase Inhibitor, and Reduced Hydrocortisone in CAH. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae824

Vancouver

Merke DP, Mallappa A, Parker M, Sukin C, Kulkarni SE, Keil MF, et al. Adult Height Following Prepubertal Treatment With Antiandrogen, Aromatase Inhibitor, and Reduced Hydrocortisone in CAH. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgae824

BibTeX
@article{Merke2025,
  author = {Merke, Deborah P and Mallappa, Ashwini and Parker, Megan and Sukin, Charles and Kulkarni, Sarah E and Keil, Margaret F and Van Ryzin, Carol and Hill, Suvimol Chirathivat and Reynolds, James C and Cutler, Gordon B and Sinaii, Ninet},
  title = {Adult Height Following Prepubertal Treatment With Antiandrogen, Aromatase Inhibitor, and Reduced Hydrocortisone in CAH},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  doi = {10.1210/clinem/dgae824}
}
Kostenlos starten →